Venus Continues To Drive TAVR In China By Licensing In Australian Start-Up Tech

Venus Medtech has agreed a licensing deal with Endoluminal Sciences, an Australian start-up with technology to prevent paravalvular leakage and improve TAVR outcomes.

Transcatheter aortic valve replacement implantation TAVR TAVI minimally invasive surgery for treatment Aortic stenosis AS blocked

Venus MedTech, the leading maker of transcatheter aortic heart valve replacement (TAVR) devices in China, has licensed Australia-based Endoluminal Sciences’ active anti-paravalvular leak (PVL) technology, which will be used in Venus’ TAVR products sold in China.

PVL is often called the Achilles’ heel of TAVR. Occurring in the majority of patients undergoing TAVR, its severity is...